… Erlotinib was administered daily at the same time each day … , erlotinib was continued daily
until intolerable toxic effect or … monotherapy with combination chemotherapy and erlotinib, in …

… shown high efficacy and low toxicity for NSCLC. In particular, combining erlotinib with the
VEGF … Our meta-analysis indicates that compared with monotherapy, erlotinib+bevacizumab …

… Its clinical applications, evidence-based efficacy and toxicity as well as … erlotinib combination
therapies (mainly with targeted drugs) randomised against erlotinib as monotherapy has …

… A direct link between erlotinib monotherapy and coagulopathy seems less likely; there are
no reports in the literature to support such a hypothesis. Two cases of patients with pancreatic …

… established the activity and manageable toxicity of erlotinib plus bevacizumab in … and
erlotinib was compared with erlotinib monotherapy to evaluate activity in patients with non-small-…

… G3-5 toxicities were rash and diarrhea in studies using both erlotinib monotherapy and
combination therapy. Furthermore, the results showed that, when using erlotinib plus mAbs, the …

… the correlation between a spectrum of cutaneous toxicities from EGFR inhibition and drug …
using erlotinib monotherapy, who experienced a spectrum of cutaneous toxicities, including …

… 15 of a 28-day cycle as monotherapy (Part A) or in combination with erlotinib at the FDA-…
monotherapy or in combination with erlotinib. Secondary objectives included safety and toxicity …

… and was associated with expected toxicities. However, only a … daily in patients with non–small
cell lung cancer not selected … establish the efficacy of erlotinib monotherapy with a phase 2 …

… The dose of TKI was reduced to 1 tablet every other day because of toxicity or economic …
IV NSqCLC with a clinical benefit from TKI monotherapy. Our data may aid expansion of the …